Connection
Eric Wu to Molecular Targeted Therapy
This is a "connection" page, showing publications Eric Wu has written about Molecular Targeted Therapy.
|
|
| |
Connection Strength |
|
 |
|
 |
| |
0.194 |
|
|
|
-
Signorovitch JE, Betts KA, Reichmann WM, Thomason D, Galebach P, Wu EQ, Chen L, DeAngelo DJ. One-year and long-term molecular response to nilotinib and dasatinib for newly diagnosed chronic myeloid leukemia: a matching-adjusted indirect comparison. Curr Med Res Opin. 2015 Feb; 31(2):315-22.
Score: 0.089
-
Signorovitch J, Ayyagari R, Reichmann WM, Wu EQ, Chen L. Major molecular response during the first year of dasatinib, imatinib or nilotinib treatment for newly diagnosed chronic myeloid leukemia: a network meta-analysis. Cancer Treat Rev. 2014 Mar; 40(2):285-92.
Score: 0.082
-
Macalalad AR, McAuliffe M, Yang H, Kageleiry A, Zhong Y, Wu EQ, Shonukan O, Bonthapally V. The epidemiology and targeted therapies for relapsed and refractory CD30+ lymphomas. Curr Med Res Opin. 2015 Mar; 31(3):537-45.
Score: 0.023